Adrenocortical carcinoma (ACC) is a rare and malignant tumor. The main treatment is primary surgical resection with or without mitotane therapy. The role of radiation therapy is still controversial. We aim to investigate the survival efficacy of radiotherapy in a large population-based cohort.
Introduction
Adrenocortical carcinoma (ACC) is a highly malignant and rare tumor with a median of 35.2 months overall survival time. [1] Surgical resection is still the mainstay treatment for resectable ACCs and even some metastatic cases. [2, 3] More than half the patients with ACC experienced tumor recurrence after surgery. [4, 5] Adjuvant treatment is needed to control and delay tumor progression. Mitotane, as an adrenotoxic agent that blocks cortisol synthesis, was suggested to be efficient for reducing recurrence risk, [6] but validation trial is still needed.
Moreover, whether adjuvant mitotane after surgery would improve overall survival is not consistent. [6, 7] In addition, the mitotane plasma levels should be continuously monitored. [4] Radiotherapy is an alternative choice for ACC patients. It is mainly applied in advanced ACC patients for palliative care. [3, 8] ACC is deemed to be resistant to radiation therapy based on previous case series. Recently, radiotherapy has demonstrated benefits through reducing recurrence risk. However, the effect of radiation therapy is still controversial. [7, [9] [10] [11] [12] The bone of contention is whether radiotherapy improves oncological outcomes. We intended to investigate the effect of radiotherapy using a national population-based database with a large sample size.
Methods

Data acquisition and selection
We queried the Surveillance, Epidemiology, and End Results (SEER) database for cases diagnosed with ACC. Cases were identified from the SEER * stat client using the International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3). The initial condition was set as Site Recode B ICD-O-3/WHO 2008: Adrenal Gland. In all, 5321 cases with an adrenal malignant tumor were identified. After that, inclusion and exclusion criteria were applied. The screening conditions were ACC, being an adult, first tumor, and unilateral ACC. Patients without survival data or deterministic treatment modalities were excluded. Ultimately, 530 cases without missing data were identified for analysis. Ethical approval was not needed because the study was exempt from Institutional Review Board review. Variables included age, race, gender, marital status, tumor laterality, surgery, regional lymph node dissection (RLND), tumor size, and tumor stage. For tumor stage, we used the European Network for the Study of Adrenal Tumors (ENSAT) staging system [13] to evaluate the ACC stage according to the codes of the Collaborative Stage (http://cancerstaging.org/cstage/ about/Pages/default.aspx). Stage I and stage II were combined and classified as the reference. The end outcomes were overall survival and cancer-specific survival.
Statistical analysis
Continuous variables were described with medians and interquartile range (IQR), and Mann-Whitney U tests were used to compare the differences between the groups. For categorical variables, we used Fisher exact test to evaluate the differences between the 2 groups. The primary outcome was overall survival. For cancer-specific survival, we adopted the cause of death listed in the SEER dataset. The follow-up cutoff date was December 31, 2013. A hazard ratio (HR) and its 95% confidence interval (95% CI) were used to estimate the risk of mortality from multivariate Cox regression analysis. Compared with traditional multivariate analysis incorporating numerous independent variables, we also performed propensity score analysis, including propensity score adjustment (PSA), inverse probability treatment weighting (IPTW), standardized mortality ratio weighting (SMRW), and propensity score matching (PSM). PSM was performed using the 1:1 nearest-neighbor method. For the propensity score matching cohort, survival differences were visualized and tested by the Kaplan-Meier method. All statistical analyses were performed using Stata 14.2 (Stata Corp, College Station, TX). A 2-tailed P value less than .05 was considered statistically significant.
Results
Five hundred thirty cases were identified after inclusion and exclusion criteria. All cases were diagnosed from 2004 to 2013 (relatively modern samples due to consideration of radiation technique development). Among them, 74 patients received radiation therapy. Three hundred eighteen patients (318/530) died during follow-up. The distribution of tumor stage was significantly different between the radiotherapy and no radiotherapy groups (P=.002). No differences between the 2 groups were observed on age, gender, race, marital status, tumor laterality, surgery, tumor size, or RLND status (Table 1) . Table 2 presents the traditional multivariate survival analysis of overall and cancer-specific survival. Radiotherapy did not increase the overall survival (HR 0.794, 95% CI 0.550-1.146, P=.218) or cancer-specific survival (HR 0.842, 95% CI 0.574-1.236, P=.388). Prognostic factors were age, surgery, and tumor stage. Table 3 summarizes the results of the various propensity score analysis. The results consistently presented no survival benefits regardless of the use of PSA, IPTW, SMRW, and PSM. After propensity score matching, the survival curves of the 2 groups were similar (Fig. 1) . The P values of the logrank tests were .7223 and .8051 for overall survival and cancer-specific survival, respectively. Considering the survival difference, we performed a subgroup survival analysis stratified by tumor stage. We stratified the stage into 2 subgroups. Group 1 was stage I/II and stage III, group 2 was stage IV. Overall mortality risk for radiation was similar to nonradiation patient in group 1 (HR 1.026, 95% CI 0.599-1.757, P=.926) and group 2 (HR 0.807, 95% CI 0.484-1.344, P=.410), respectively. All results above indicated the stability of the survival analysis results.
Discussion
In this study, we used a relatively large cohort to demonstrate the efficacy of radiotherapy on ACC. All results consistently showed that no oncologic survival improvement from radiotherapy was observed for ACC patients. The results were stable on the basis of traditional multivariate analysis and propensity score analysis. An incisive criticism of the aforementioned studies is that all previous outcomes were based on a limited sample size that may have had low statistical power to demonstrate significance. We included 530 complete ACC cases with 318 events during followup. The outcomes were similar to previous studies. [1, 11] Because the ACC was highly malignant, the majority of causes of death were ACC-related causes. Thus, cancer-specific mortality risk was similar to overall mortality.
ACC was deemed to be radiation-resistant, and only a very small portion of patients received radiotherapy, mainly as palliative treatment. It was reported that radiotherapy could reduce the risk of local recurrence but would not change the overall survival. [10, 14] The benefit of recurrence control seemed to conflict with null results. These null results may be due to the intrinsically high malignancy of ACC. Mild benefits could not [10] In the study by Else et al, [1] it was mitotane, not radiation, that improved recurrence-free survival in the multivariate analysis. The results of this study also indicated the synergism of mitotane combined with radiation. [1] Despite no overall survival improvement, radiotherapy has some potential benefits. However, the side effects of radiation are assignable. Radiation is given to the adrenal bed including multiple organs and tissues. Thus, radiotherapy for ACC could damage adjacent organs and tissues such as the kidney, vascular vessels, spinal cord, diaphragm, and stomach. A precise and modest radiation dose is critical. However, the literature reported that adverse effects of radiotherapy in ACC were mild to moderate. [15] Newly developed radiation techniques such as stereotactic body radiation therapy (SBRT) have been reported to be effective for controlling metastatic lesions. [16] In summary, radiotherapy could not improve overall survival but may ameliorate tumorrelated symptoms and achieve local control of ACCs.
Our study has some limitations. This study is based on the SEER database and may have sizeable selection bias. Massive missing data are the flaw for the SEER dataset. Some important roles were not included in the analysis. For instance, the doses and courses were not explicitly recorded. These factors played a key role in terms of the efficacy of the radiotherapy. [15] As the development of radiation technique, different radiation modalities used by different medical teams could lead to variations in outcomes. In addition, the number of patients who received radiotherapy was relatively small (74 patients) and accounted for almost 14% of the total included population. The modality of radiation was not included. It could affect the effect of radiation therapy. The mitotane administration situation was not evaluated, although the contention of efficacy existed. [6, 7] The resection margin status was not assessed due to no related records. Resection margin played a critical role in cancer survival. For future clinical studies, multiple center collaborative cooperation is critically urgent. Table 2 Multivariate Cox regression for radiotherapy on overall survival and cancer-specific survival.
Variables
Overall survival P Cancer-specific survival P RLND=regional lymph node dissection. Table 3 Propensity score analysis for the efficacy of radiotherapy on overall survival and cancer-specific survival.
Propensity score methods Overall survival P Cancer-specific survival P IPTW=inverse probability of treatment weighting, PSA=propensity score adjustment, PSM=propensity score matching, SMRW=standardized mortality ratio weighting.
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Conclusion
Radiotherapy did not improve overall or cancer-specific survival in ACC patients. Further confirmation is needed from multiinstitutional prospective studies in the future.
